Biocon rolls out new diabetes and weight-loss treatments in the Netherlands

Business Dec 15, 2025

Biocon just launched its first GLP-1 drug-device combo in the EU, bringing Diavorin for diabetes and Vobexoryn for weight management to the Netherlands.
Both got the green light from Dutch regulators earlier this year, marking a significant development for Biocon's presence in Europe.

More global moves (and a quick look at their stock)

Biocon Biologics, a subsidiary of Biocon, also struck a deal with Regeneron and Bayer to take its eye drug Yesafili beyond North America, now reaching Europe and more regions.
Even with these bold launches, Biocon's stock dipped 8.5% over the past month.